Third, for outcomes reported for all SGLT2 inhibitor users or placebo groups, we could not extract data for subgroup analysis, e.g. DM/non-DM, HF/non-HF, CKD/non-CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.